Neurocrine Biosciences (NBIX) Receivables - Other (2019 - 2025)

Neurocrine Biosciences (NBIX) has reported Receivables - Other for 7 consecutive years, with $20.5 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 42.36% year-over-year to $20.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.5 million (up 42.36% YoY), and the FY2025 full-year result was $20.5 million, up 42.36% from the prior year.
• Receivables - Other climbed to $20.5 million in Q4 2025 per NBIX's latest filing, from $14.4 million in the prior quarter.
• Across five years, Receivables - Other topped out at $20.5 million in Q4 2025 and bottomed at $2.2 million in Q4 2021.
• Historically, Receivables - Other has averaged $6.8 million across 5 years, with a median of $4.4 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Receivables - Other slumped 40.54% in 2021, then surged 186.36% in 2024.
• Over 5 years, Receivables - Other stood at $2.2 million in 2021, then surged by 113.64% to $4.7 million in 2022, then jumped by 138.3% to $11.2 million in 2023, then climbed by 28.57% to $14.4 million in 2024, then surged by 42.36% to $20.5 million in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $20.5 million, $14.4 million, and $12.6 million for Q4 2025, Q4 2024, and Q1 2024 respectively.